Background Apolipoprotein A5 (apoA5) is a recently described liver-specific protein that has been shown to influence triglyceride (TG) metabolism. ApoA5 transgenic mice display dramatically reduced TG levels, while in contrast apoA5 deficiency in humans was reported to result in marked hypertriglyceridemia. ApoA5 exerts its extracellular effects by increasing lipolysis of TG-rich lipoproteins, while in vitro data suggest additional intrahepatic effects. Methods In this study the authors set out to investigate a possible role of apoA5 in non-alcoholic fatty liver disease (NAFLD). We thus determined hepatic apoA5 expression in 15 obese subjects with histologically proven NAFLD undergoing bariatric surgery. In addition, the authors established a hepatic cell culture model of apoA5 knockdown by transfecting human hepatoma cells (HepG2) with apoA5 small interfering (si) RNA, and determined intracellular TG content and expression levels of key enzymes and transcription factors of intrahepatic lipid metabolism in these cells. Results Pronounced weight loss and associated histologically verified improvement of hepatic steatosis were accompanied by significant reductions of hepatic apoA5 mRNA expression levels. Significant apoA5 knockdown in HepG2 cells resulted in a marked decrease of intracellular TG content. When HepG2 cells were cotransfected with apoA5 and peroxisome proliferatoractivated receptor gamma (PPARg), reductions in hepatic TG accumulation were significantly less pronounced when compared to apoA5 siRNA transfected HepG2 cells. Conclusions In obese subjects, hepatic apoA5 mRNA expression decreases after weight loss and improvements in hepatic steatosis. The authors' in vitro data demonstrate that apoA5 influences intrahepatic TG metabolism and that these intracellular effects of apoA5 are accompanied by changes in PPARg mRNA expression. In summary, the data suggest that as well as several other factors, apoA5 might be involved in the pathogenesis of hepatic steatosis.
INTRODUCTION
The term NAFLD comprises a wide spectrum of clinical entities ranging from simple steatosis and steatohepatitis to fibrosis and cirrhosis. 1 NAFLD is strongly associated with obesity and is found in up to 91% of severe obese patients undergoing bariatric surgery. 2 Its close association not only with obesity but also with insulin resistance and dyslipidemia, led to the hypothesis that NAFLD is the hepatic manifestation of the metabolic syndrome. 3 Pathophysiologically it has been debated that excessive intrahepatic lipid accumulation, oxidative stress, ER stress, increased proinflammatory stimuli and alterations in adipocytokine metabolism have been involved in the development and progression of NAFLD. 4 Lipid deposition within the liver in NAFLD might result from both genetic and environmental factors that directly or indirectly disturb intrahepatic metabolism. These factors can excite their effects either by influencing increased availability of fatty acids (FA), enhanced de novo lipogenesis, impaired b-oxidation or alterations in assembly or secretion of lipoproteins. 5 6 Apolipoprotein A5 (apoA5) is a recently found apolipoprotein that exhibits a major impact on lipid metabolism. It was first described independently by two different groups. Pennacchio et al. 7 reported on a gene encoding for a new apolipoprotein influencing plasma TG levels and at the same time, Van der Vliet et al. 8 described a novel protein associated with liver regeneration. The APOA5 gene is located within the APOA1/C3/A4/ A5 gene cluster on chromosome 11q23 and its expression is tightly controlled by several transcription factors like peroxisome proliferator-activated receptor alpha (PPARa) and sterol regulatory
Significance of this study
What is already known about this subject?
< ApoA5 is a liver-specific protein with increased expression in states of hepatic regeneration. < ApoA5 transgenic mice display reduced levels of serum triglycerides. < ApoA5 accelerates lipolysis of triglyceride (TG)-rich lipoproteins e intracellular effects have been proposed but are not well understood yet.
What are the new findings?
< ApoA5 affects intrahepatic TG metabolism by lowering intracellular TG content. < Effects are partially mediated by PPARg. < Consistent with these in vitro data, improved liver steatosis after weight loss is accompanied by decreased expression of hepatic apoA5 mRNA.
How might it impact on clinical practice in the foreseeable future?
< Our in vitro and in vivo data suggest that ApoA5 might be involved in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Apo5 could evolve as a new treatment target.
element-binding protein-1c (SREBP-1c) with a well established impact on lipid metabolism. 9e11 ApoA5 is specifically expressed in the liver and secreted only in very small amounts. 12 13 Plasma apoA5 is primarily associated with high density lipoprotein and very low density lipoprotein particles. 13 In mice, overexpression of apoA5 results in decreased plasma TG levels, whereas apoA5 (À/À) mice display significantly increased TG levels. 7 14 In humans, data about the impact of apoA5 on lipid metabolism are less clear: both positive and negative correlations between apoA5 and plasma TG levels have been described. 15e17 However, strong associations between apoA5 polymorphisms and elevated plasma TG levels have been reported. 18 19 Mechanistically, extracellular effects by activating lipoprotein lipase (LPL) have been described. 20 Its liver-specific expression and low concentrations of circulating protein suggest intracellular effects of apoA5 also: a role in storage and mobilisation of intracellular lipids has been proposed. 21 Furthermore, apoA5 seems to be associated with intracellular lipid droplets 22 and very recently published data revealed effects of apoA5 on intrahepatic TG accumulation. 23 However, the exact underlying mechanisms of apoA5's functions and its sheer magnitude are not fully understood yet.
The aim of this study was to elucidate a possible role of apoA5 in NAFLD. We thus determined intrahepatic apoA5 in obese subjects with histologically proven NAFLD undergoing bariatric surgery in a prospective design and established an in vitro cell culture model of siRNA knockdown for studying its role in intracellular lipid metabolism.
MATERIALS AND METHODS Subjects
Fifteen obese patients, 3 men and 12 women undergoing bariatric surgery (Swedish adjustable gastric banding or gastric bypass) participated in our study. Detailed inclusion and exclusion criteria have been described in detail elsewhere. 24 In short, patients with any endocrine or metabolic disorder, especially diabetes, as well as patients with severe renal, hepatic or cardiovascular disease were excluded from the study. Subjects taking hypolipidemic, immunosuppressive or glucose-lowering drugs, as well as patients with a history of excessive drinking or other liver diseases, including alcoholic liver disease, viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, haemochromatosis, Wilson's disease or a 1 -antitrypsin deficiency were excluded from the study. Liver biopsies were performed before and on an average of 1361 months after bariatric surgery. The study protocol was approved by the local ethics committee and all patients gave their informed written consent before participation.
Clinical and laboratory measurements
Blood samples were drawn after an overnight fast, rapidly processed or stored at À808C after centrifugation. Lipid, glucose, insulin, ASTand ALT levels were determined using commercially available kits. Insulin sensitivity was estimated by HOMA index which was calculated using the formula:
HOMA¼fasting insulin (mU/ml)3plasma glucose (mmol/l)/ 22.5. 25 Body composition was determined by impedance analysis using InBody 3.0 Body Composition analyser from Biospace Europe (Dietzenbach, Germany).
Histological assessment
Sections (4 mm) were prepared from formalin-fixed paraffinembedded tissue specimens, deparaffinised and rehydrated in graded alcohols. 26 Histological scoring of liver steatosis was assessed by using a four-grade classification modified from Kleiner et al.: 0, absent; 1, <5%; 2, 5e33%; 3, 33e66%; 4, >66%.
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Cell culture
Human hepatoma cells HepG2 (ATCC, Manassas, Virginia, USA) were maintained at 378C and at 5% CO 2 /95% air in RPMI 1640 medium (Biochrom KG, Berlin, Germany) supplemented with 10% fetal bovine serum (Life Technologies, Rockville, Maryland, USA), 2 mM L-glutamine (Biochrom KG, Berlin, Germany) and 1% penicillin/streptomycin (Seromed, Berlin, Germany). Fresh medium was added every 3 days and cells were split at a ratio of 1:4 every 7 days.
siRNA transfection
HepG2 cells were transfected with small interfering RNA (siRNA) targeting apoA5 (Hs_APOA5_6 HP Validated siRNA, Qiagen, Hilden, Germany), PPARg (Hs_PPARG_1, Qiagen, Hilden, Germany) or nonsilencing control siRNA (Qiagen, Hilden, Germany) using the lipotransfection method (HiPerfect, Qiagen, Hilden, Germany) according to the manufacturer's instructions. Transfected cells were maintained in cell culture transfection media containing 50 nM or 100 nM siRNA and HiPerfect Transfection reagent for up to 72 h. The silencing effect of apoA5 siRNA transfection was quantified by Western blotting and immunodetection as well as by fluorescence-based real-time PCR. The silencing effect of PPARg siRNA transfection was monitored by fluorescence-based real-time PCR. All siRNA transfection experiments were performed in duplicates: the number of independent experiments performed in each setting is shown in the Results section.
Western blotting
Cell membranes were lysed with cytoplasmatic lysis buffer, containing 40 mM KCl, 25 mM Tris and 1% Triton. Obtained cell proteins were transferred to nitrocellulose membranes after quantification using Lowry's method. 28 ApoA5 protein was detected using commercially available monoclonal apoA5 antibody (Novus Biologicals, Littleton, Colorado, USA) and HRPconjugated secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, Philadelphia, USA). Visualisation was performed by chemiluminescence (Amersham ECL Plus Western Blotting Reagent, GE Healthcare, Wien, Austria). Recombinant human apoA5 produced as previously described was used as a positive control. 13 ApoA5 protein levels were controlled for b-Actin protein (Sigma-Aldrich, St. Louis, Missouri, USA).
TG quantification
HepG2 cells were harvested with trypsin, centrifuged, washed and afterwards resuspended in 0.1 M NaOH. Subsequently, the solution was sonificated and centrifuged again at 13 200 rpm for 10 min. The TG content of supernatant was determined using a commercially available enzymatic kit (Roche Diagnostics GmbH, Mannheim, Germany) on an automated analyser (Roche Hitachi Automatic Analyser 902). TG contents were controlled for total cell protein levels as determined by Lowry's method. 28 RNA isolation, reverse transcription and fluorescence based real-time PCR Isolation of total RNA was performed using Trizol reagent for liver biopsies (Invitrogen, Paisley, Scotland, UK) and using RNABee reagent for HepG2 cells (AMS Biotechnology, Abingdon, UK). Reverse transcription was performed using the Omniscript Reverse Transcription kit (Qiagen, Hilden, Germany) according to the manufacturer 's instructions. M-RNA of apoA5, diacyl-glycerol-acyl-transferase-2 (DGAT-2), carnitin-palmitoyl-transferase-1 (CPT-1), fatty-acid-synthase (FAS), glycerol-3-phosphate acyltransferase 1 (GPAT-1), sterol regulatory element-binding protein-1c (SREBP-1c), peroxisome proliferator-activated receptor alpha (PPARa) and peroxisome proliferator-activated receptor gamma (PPARg) were estimated by using the TaqMan real-time PCR method. Briefly, 2.5 ml of each reverse transcription reaction mixture served as a template in a 25 ml reaction mixture containing 12.5 ml TaqMan Universal Polymerase Master Mix (Applied Biosystems, Foster City, California, USA), 2.25 ml (10 nmol/ml) of each oligonucleotide primer (MWG Ebersberg, Germany), 0.5 ml of TaqMan probe (10 nmol/ml) (Microsynth, Baglach, Switzerland) and 5 ml aqua dest. TaqMan probes were labelled with the reporter fluorescent dye 6-carboxyfluorescein (FAM) at the 5 9 end and with the quencher 6-carboxy-tetramethyl-rhodamine (TAMRA) at the 3 9 end. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was quantified using the TaqMan GAPDH control reagents (Applied Biosciences, Foster City). Results were expressed as parameter/GAPDH cDNA ratio.
Serially diluted cDNA prepared from human HepG2 cells were used for the standard curve. The PCR reactions were performed in duplicate in MicroAmp 96 well reaction plates (Applied Biosystems, Foster City) using the Applied Biosystems 7900HT Fast Real Time PCR system (Applied Biosystems, Foster City). Amplification conditions were 2 min at 508C, 10 min at 958C, followed by 40 cycles of 15 s at 958C and 1 min at 608C. Results were analysed using the Sequence Detector 2.3 software. Oligonucleotide primers and TaqMan probes were designed using Primer express software (Perkin-Elmer Applied Biosystems, Warrington, UK). Oligonucleotide primers and TaqMan probes are listed in table 1.
Statistical analysis
Differences between follow-up parameters were calculated using the Student's paired t test for metric parameters and Wilcoxon test for nominal parameters. In case of non-normal distribution as assessed by Shapiro-Wilk test, variables were log transformed to achieve more normal distribution. In the case of multiple comparisons, correction was performed using the Bonferroni method. Distinctions between different groups were determined by using one-way ANOVAs or Kruskal-Wallis and MannWhitney test followed by Bonferroni adjustment for multiple testing. Descriptive data are expressed as means6SD except for hepatic mRNA expression levels of apoA5 before and after bariatric surgery (means6SEM).
For all calculations statistical significance was inferred at a two-tailed p value of less than 0.05. SPSS for Windows (version 17.0) was used for statistical analysis.
RESULTS
Clinical data
Mean weight loss of 18.4568.85 kg was accompanied by improvements in parameters of lipid and glucose metabolism as shown in table 2. Histological scores of steatosis significantly improved from 2.6061.12 to 1.2760.96 (p<0.01) while grade of fibrosis and inflammation were unaffected by pronounced weight loss (grade of fibrosis: before surgery 0.6260.51 vs 0.5060.52 after surgery, p¼0.56; grade of inflammation: before surgery 0.7560.45 vs 0.6260.52 after surgery, p¼0.56). Hepatic apoA5 mRNA expression significantly decreased by 41% (p¼0.02) after pronounced weight loss ( figure 1) . No significant correlations were found between apoA5 mRNA expression and HOMA index, TG levels or grade of steatosis, respectively (data not shown). Determination of hepatic PPARg mRNA expression showed no significant alteration during observation time (data not shown).
Cell culture results
ApoA5 siRNA knockdown
Transfection of HepG2 cells with apoA5 siRNA declined apoA5 protein content in a dose-and time-dependent manner (data not shown) (n¼3). Seventy-two hours after transfection of human hepatoma cells (HepG2) with 50 nM apoA5 siRNA knockdown efficiency was 94%619% (p<0.001) as quantified by Western blot analysis (figure 2A).
TG content
TG content of HepG2 was determined 72 h after transfection of HepG2 cells with 50 nM apoA5 siRNA or nonsilencing siRNA. SiRNA knockdown of apoA5 by 94% resulted in significantly decreased intracellular TG (reduction: 36%616%) (p<0.001) (n¼11) when compared to HepG2 cells transfected with 50 nM nonsilencing siRNA (figure 2B).
mRNA expression levels of key enzymes and transcription factors of hepatic lipid metabolism
To further characterise the effects of apoA5 siRNA knockdown in HepG2 cells we determined mRNA expression levels of key enzymes and transcription factors of hepatic fatty acid metabolism. mRNA expression levels of DGAT-2, CPT-1, FAS, GPAT-1, SREBP-1c or PPARa were similar in apoA5 siRNA transfected HepG2 cells and cells transfected with non-silencing siRNA (data not shown) suggesting neither direct nor indirect effects of apoA5 on these enzymes or transcription factors. Remarkably, after correction for multiple testing, PPARg mRNA expression levels were significantly increased by 83%640% (p<0.01) (n¼4) in apoA5 siRNA transfected HepG2 cells when compared to control cells transfected with nonsilencing siRNA (figure 3). To elucidate whether TG reduction in apoA5 siRNA transfected cells was dependent on PPARg activity, we co-transfected HepG2 cells with apoA5 siRNA and PPARg siRNA resulting in a reduction of apoA5 mRNA expression by 76%622% and concomitantly of PPARg mRNA expression by 62%610% as determined by fluorescence-based real-time PCR (n¼3). Transfection of HepG2 with PPARg siRNA alone resulted in a significant decrease in PPARg by 78%610% (data not shown).
As shown in figure 4 , co-transfection with apoA5 siRNA and PPARg siRNA was associated with significantly decreased intracellular TG content. However, reduction in TG content was significantly less pronounced in apoA5-and PPARg-siRNA cotransfected cells when compared to cells transfected with apoA5 siRNA only. When cells were transfected with increasing concentration of apoA5 siRNA (10nM, 25 nM, 50nM) and 100 nM of PPAR or 100 nM of nonsilencing siRNA apoA5 knockdown was similar in HepG2 cells co-transfected with apoA5 and PPARg siRNA and cells co-transfected with apoA5 and nonsilencing siRNA. PPARg knockdown was comparable in HepG2 cells transfected with variable concentrations of apoA5 siRNA (data not shown). Intracellular TG content was significantly higher in apoA5 and PPARg siRNA co-transfected cells when compared to apoA5 and nonsilencing siRNA co-transfected cells at each tested apoA5 siRNA concentration (p<0.01). In both, apoA5/PPARg siRNA co-transfected cells and apoA5/nonsilencing siRNA co-transfected cells' TG content decreased with increasing concentrations of apoA5 siRNA (figure 5). Figure 1 The individual percentage and total changes of apoA5 mRNA expression levels expressed as apoA5/GAPDH cDNA ratio in 15 obese patients before and after weight loss are shown (means6SEM). 
DISCUSSION
NAFLD is one of the most common chronic liver diseases in the developed world. It has been shown that NAFLD is closely associated with obesity: up to 91% of morbidly obese patients undergoing bariatric surgery display a fatty liver phenotype.
However, pathophysiological mechanisms of NAFLD are not fully understood.
In this study we set out to investigate a possible role of apoA5 in NAFLD. Bariatric surgery has not only been demonstrated to be the most effective and sustaining treatment of morbid obesity but has also been shown to be associated with significant improvements in hepatic steatosis, which prompted us to investigate the impact of bariatric surgery on hepatic apoA5 mRNA expression levels in morbidly obese subjects with histologically proven NAFLD. In accordance with previous studies, 29 30 the grade of steatosis significantly improved with pronounced weight loss. In parallel, we found a significant reduction in intrahepatic apoA5 mRNA content in these patients. Lacking correlation between hepatic apoA5 mRNA expression levels and grade of steatosis in our study might be explained by multifarious determinants of hepatic TG accumulation in humans. ApoA5 gene expression has been shown to be downregulated by insulin, 31 suggesting that decreased apoA5 levels might result from improved insulin action in weight-reduced patients. In contrast to previous studies 7 14 with apoA5 overexpressing mice we detected no significant correlations of apoA5 expression with plasma TG levels in our study group. This discrepancy might be explained by possible interspecies variances and supraphysiological expression levels used in animal function studies. Additionally, the size of our human study might have been too small to control for multiple determinants of serum TG levels.
To elucidate whether the observed reduction in hepatic apoA5 mRNA in weight-reduced subjects has a causative role in improvement of steatosis in these patients or is just considered to be an epiphenomenon, we established a cell culture model of apoA5 knockdown by transfecting human hepatoma HepG2 cells with apoA5 siRNA. Remarkably, we found that pronounced apoA5 suppression results in a significant reduction in intracellular TG content, suggesting that apoA5 e beyond its known extracellular effects e might additionally exert intrahepatic effects resulting in decreased lipid accumulation. Our finding is supported by results from Shu et al. who reported significantly increased TG contents in livers of apoA5 transgenic (Tg) mice. 23 We thus hypothesise that reduced intrahepatic apoA5 mRNA levels in weight-reduced patients have a causal role in improvement of steatosis rather than result from increased insulin-sensitivity.
To further investigate the underlying molecular mechanisms by which apoA5 directly or indirectly influences intrahepatic lipid metabolism we determined mRNA expression levels of key enzymes and transcription factors involved in hepatic lipid metabolism. Namely, mRNA expression levels of GPAT-1 and DGAT-2 e two key enzymes in TG synthesis 32 33 which have been shown to be involved in development of steatosis 34 e were determined. Furthermore, we measured CPT-1 and FAS mRNA expressions in apoA5 siRNA transfected cells. CPT-1 is a ratelimiting enzyme of mitochondrial b-oxidation 35 with a wellknown impact on development of NAFLD. 36 FAS is a key enzyme in fatty acid synthesis and thus might also have a crucial role in NAFLD by increasing the intrahepatic pool of fatty acids. 5 Taken together, none of these key modulators' mRNA expressions were significantly altered by apoA5 knockdown. We conclude from these results that apoA5, neither in a direct nor in an indirect way, affects transcriptional regulation of critical enzymes of intrahepatic lipid metabolism. Our data further indicate that the reduction in intracellular TG content in apoA5 siRNA-treated HepG2 cells does not result from altered mRNA expressions levels of GPAT-1, DGAT-2, FAS or CPT-1.
Expression levels of apoA5 are tightly controlled by transcription factors with a major impact on lipid as well as glucose metabolism. Beyond others, SREBP-1c and PPARa have been described to influence apoA5 expression level. 10 11 We found that neither SREBP-1c nor PPARa mRNA expression is altered in apoA5 siRNA transfected HepG2 cells, suggesting that resulting reduced intracellular TG content is at least not primarily mediated by SREBP-1c or PPARa.
PPARg is a member of the nuclear receptor superfamily with multifarious functions in regulating energy homeostasis, influencing inflammatory reactions as well as promoting adipogenesis via transcriptional control of target genes. Among others, PPARg activity is regulated by polyunsaturated fatty acids, eicosanoids and thiazolidinediones (TZDs). 37 TZDs e beyond their antidiabetic properties e have also been shown to be effective at least for short-time treatment of non-alcoholic steatohepatitis.
38e41 Remarkably, we found that PPARg mRNA expression is significantly upregulated in HepG2 cells with pronounced apoA5 knockdown, suggesting that increased PPARg mRNA expression might probably be responsible for decreased TG content in these cells. In order to test this hypothesis, we transfected HepG2 cells with either apoA5 or PPARg siRNA alone or co-transfected HepG2 cells with both apoA5 and PPARg siRNA. We found that apoA5 but not PPARg knockdown results in a significant decrease in intracellular TG content. Remarkably, intracellular TG reductions were significantly less pronounced in apoA5 and PPARg co-transfected HepG2 cells when compared with HepG2 cells transfected with apoA5 siRNA alone. Additionally, we found that reductions in intracellular TG levels in HepG2 cells co-transfected with increasing concentrations of apoA5 siRNA and a given concentration of PPARg were less pronounced than declines found in HepG2 cells co-transfected with increasing concentrations of apoA5 siRNA and a given concentration of nonsilencing RNA. We conclude from these results that reduced intracellular TG content in HepG2 cells with apoA5 knockdown is partially mediated by PPARg. We suggest that increased PPARg mRNA expression might rather result from changes in intracellular lipid metabolism such as quantitative or qualitative changes in polyunsaturated fatty acids in apoA5-deficient cells than from a direct effect of apoA5 on PPARg. One would expect a moderate increase in PPARg mRNA expression in weightreduced subjects displaying lower apoA5 mRNA expression levels and improved steatosis. However, in our study PPARg mRNA expression levels remained unchanged after bariatric surgery, which might be explained by the small number of tested subjects.
In summary, we found that apoA5 influences TG metabolism in vitro. Our data suggest that PPARg might be involved in these apoA5-mediated effects on hepatic TG accumulation. These in vitro results are fully in accordance with our clinical data showing that apoA5 mRNA expression decreases significantly after weight loss in morbidly obese subjects with NAFLD. Beyond several other factors such as DGAT 2 34 42 43 , MTP 44 45 or adipocytokines 46 apoA5 might be another player in the development of NAFLD by affecting intrahepatic lipid metabolism.
